Comparative Pharmacology
Head-to-head clinical analysis: HALFAN versus MALMOREDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALFAN versus MALMOREDE.
HALFAN vs MALMOREDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HALFAN (halofantrine) is an antimalarial agent that acts as a blood schizonticide. It is thought to inhibit the polymerization of heme into hemozoin, leading to toxic accumulation of free heme within the parasite's food vacuole. It may also interfere with nucleic acid synthesis.
Malmorede is a synthetic peptide analog of thymosin alpha 1, acting as a biological response modifier. It enhances T-cell maturation and function, increases interleukin-2 production, and modulates immune response by activating dendritic cells and promoting Th1-type cytokine release.
Adults: 500 mg orally once daily.
Initial: 50 mg orally twice daily. Maintenance: 100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 10-18 hours (mean 14 hours) in healthy adults, allowing twice-daily dosing.
4-6 hours; increased in renal impairment (up to 12-15 hours).
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug; biliary/fecal elimination of metabolites approximately 20-30%.
Primarily renal: 70-80% unchanged; biliary/fecal: 20-30% as metabolites.
Category C
Category C
Antimalarial
Antimalarial